Literature DB >> 33777846

Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent.

Debbie-Ann Shirley1, Ishrya Sharma2, Cirle A Warren2, Shannon Moonah2.   

Abstract

Parasitic infections contribute significantly to worldwide morbidity and mortality. Antibiotic treatment is essential for managing patients infected with these parasites since control is otherwise challenging and there are no vaccines available for prevention. However, new antimicrobial therapies are urgently needed as significant problems exist with current treatments such as drug resistance, limited options, poor efficacy, as well as toxicity. This situation is made worse by the challenges of drug discovery and development which is costly especially for non-profitable infectious diseases, time-consuming, and risky with a high failure rate. Drug repurposing which involves finding new use for existing drugs may help to more rapidly identify therapeutic candidates while drastically cutting costs of drug research and development. In this perspective article, we discuss the importance of drug repurposing, review disulfiram pharmacology, and highlight emerging data that supports repurposing disulfiram as an anti-parasitic, exemplified by the major diarrhea-causing parasite Entamoeba histolytica.
Copyright © 2021 Shirley, Sharma, Warren and Moonah.

Entities:  

Keywords:  disulfiram (Antabuse); drug development; drug repurposing and repositioning; parasites; protein degradation

Mesh:

Substances:

Year:  2021        PMID: 33777846      PMCID: PMC7991622          DOI: 10.3389/fcimb.2021.633194

Source DB:  PubMed          Journal:  Front Cell Infect Microbiol        ISSN: 2235-2988            Impact factor:   6.073


  72 in total

1.  The bifunctional aldehyde-alcohol dehydrogenase controls ethanol and acetate production in Entamoeba histolytica under aerobic conditions.

Authors:  Erika Pineda; Rusely Encalada; Alfonso Olivos-García; Mario Néquiz; Rafael Moreno-Sánchez; Emma Saavedra
Journal:  FEBS Lett       Date:  2012-11-28       Impact factor: 4.124

2.  Cullin-RING ubiquitin E3 ligase regulation by the COP9 signalosome.

Authors:  Simone Cavadini; Eric S Fischer; Richard D Bunker; Alessandro Potenza; Gondichatnahalli M Lingaraju; Kenneth N Goldie; Weaam I Mohamed; Mahamadou Faty; Georg Petzold; Rohan E J Beckwith; Ritesh B Tichkule; Ulrich Hassiepen; Wassim Abdulrahman; Radosav S Pantelic; Syota Matsumoto; Kaoru Sugasawa; Henning Stahlberg; Nicolas H Thomä
Journal:  Nature       Date:  2016-03-31       Impact factor: 49.962

3.  Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram).

Authors:  Boris Cvek
Journal:  Drug Discov Today       Date:  2011-12-16       Impact factor: 7.851

4.  Disulfiram-like Reaction With Metronidazole: An Unsuspected Culprit.

Authors:  Morgan M Alonzo; Teresa V Lewis; Jamie L Miller
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Sep-Oct

5.  Sudden death due to metronidazole/ethanol interaction.

Authors:  S J Cina; R A Russell; S E Conradi
Journal:  Am J Forensic Med Pathol       Date:  1996-12       Impact factor: 0.921

Review 6.  Sildenafil for male erectile dysfunction: a systematic review and meta-analysis.

Authors:  Howard A Fink; Roderick Mac Donald; Indulis R Rutks; David B Nelson; Timothy J Wilt
Journal:  Arch Intern Med       Date:  2002-06-24

Review 7.  A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites.

Authors:  B Johansson
Journal:  Acta Psychiatr Scand Suppl       Date:  1992

8.  Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.

Authors:  Sukhdev S Brar; Claude Grigg; Kimberly S Wilson; Walter D Holder; Didier Dreau; Catherine Austin; Mareva Foster; Andrew J Ghio; A Richard Whorton; Grayson W Stowell; Linda B Whittall; Robert R Whittle; David P White; Thomas P Kennedy
Journal:  Mol Cancer Ther       Date:  2004-09       Impact factor: 6.261

9.  Antibacterial activity of disulfiram and its metabolites.

Authors:  K R Frazier; J A Moore; T E Long
Journal:  J Appl Microbiol       Date:  2018-10-11       Impact factor: 3.772

Review 10.  Drug repurposing and human parasitic protozoan diseases.

Authors:  Katherine T Andrews; Gillian Fisher; Tina S Skinner-Adams
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-03-24       Impact factor: 4.077

View more
  8 in total

1.  Disulfiram blocked cell entry of SARS-CoV-2 via inhibiting the interaction of spike protein and ACE2.

Authors:  Hsiao-Fan Chen; Po-Ren Hsueh; Yen-Yi Liu; Yeh Chen; Sui-Yuan Chang; Wei-Jan Wang; Chen-Shiou Wu; Ya-Min Tsai; Yu-Shu Liu; Wen-Chi Su; Yu-Chi Chou; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  VISPNN: VGG-inspired Stochastic Pooling Neural Network.

Authors:  Shui-Hua Wang; Muhammad Attique Khan; Yu-Dong Zhang
Journal:  Comput Mater Contin       Date:  2021-09-27       Impact factor: 3.860

Review 3.  An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives.

Authors:  Helena Lucia Carneiro Santos; Karina M Rebello
Journal:  Front Cell Infect Microbiol       Date:  2022-04-25       Impact factor: 6.073

4.  N,N-Dimethyldithiocarbamate Elicits Pneumococcal Hypersensitivity to Copper and Macrophage-Mediated Clearance.

Authors:  Sanjay V Menghani; Madeline P Cutcliffe; Yamil Sanchez-Rosario; Chansorena Pok; Alison Watson; Miranda J Neubert; Klariza Ochoa; Hsin-Jung Joyce Wu; Michael D L Johnson
Journal:  Infect Immun       Date:  2022-03-21       Impact factor: 3.609

5.  Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2'-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs.

Authors:  Ibrahim H Eissa; Mohamed S Alesawy; Abdulrahman M Saleh; Eslam B Elkaeed; Bshra A Alsfouk; Abdul-Aziz M M El-Attar; Ahmed M Metwaly
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

6.  Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica.

Authors:  Monica M Kangussu-Marcolino; Upinder Singh
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

Review 7.  Reactive Sulfur Compounds in the Fight against COVID-19.

Authors:  Małgorzata Iciek; Anna Bilska-Wilkosz; Michał Kozdrowicki; Magdalena Górny
Journal:  Antioxidants (Basel)       Date:  2022-05-26

Review 8.  Disulfiram in glioma: Literature review of drug repurposing.

Authors:  Shiyu Zhong; Xudong Zhang; Kunhang Li; Guojun Liu; Lishuai Li; Shanwei Tao; Bowen Zheng; Weichen Sheng; Ziyin Ye; Qichen Xing; Qingqing Zhai; Lijie Ren; Ying Wu; Yijun Bao
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.